Elevation Oncology, Inc. (ELEV)

Market Cap	38.64M
Revenue (ttm)	n/a
Net Income (ttm)	-39.70M
Shares Out	59.11M
EPS (ttm)	-0.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,137,560
Open	0.591
Previous Close	0.585
Day's Range	0.590 - 0.679
52-Week Range	0.363 - 5.830
Beta	1.24
Analysts	Strong Buy
Price Target	7.80 (+1,093.21%)
Earnings Date	Oct 31, 2024

About ELEV

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company’s lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: ELEV
• Website: https://elevationoncology.com

Analyst Forecast

According to 5 analysts, the average rating for ELEV stock is "Strong Buy." The 12-month stock price forecast is $7.8, which is an increase of 1,093.21% from the latest price.

Price Target

$7.8

(1,093.21% upside)

Analyst Consensus: Strong Buy